Health Care & Life Sciences » Biotechnology | ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
1.30
16.40
21.50
28.00
18.80
Gross Income
-
1.30
16.40
21.50
28.00
18.80
SG&A Expense
140.20
1,670.80
13,943.60
20,570.00
20,995.90
14,575.40
EBIT
140.20
1,672.10
13,960.00
20,591.50
21,023.90
14,594.20
Unusual Expense
-
3,595.80
387.90
3,592.80
4,224.80
4,948
Interest Expense
0.30
12.90
-
-
-
339.20
Pretax Income
140.50
5,280.80
14,347.90
16,998.60
16,799.10
9,985.30
Income Tax
-
-
-
-
1,908.00
536
Consolidated Net Income
140.50
5,280.80
14,347.90
16,998.60
14,891.10
9,449.30
Net Income
140.50
5,280.80
14,347.90
16,998.60
14,891.10
9,449.30
Net Income After Extraordinaries
140.50
5,280.80
14,347.90
16,998.60
14,891.10
9,449.30
Net Income Available to Common
140.50
5,280.80
22,192.50
16,998.60
14,891.10
17,901.10
EPS (Basic)
0.16
3.30
8.16
5.03
2.40
97.35
Basic Shares Outstanding
1,125.00
1,602.20
2,719.30
3,382.50
7,286.30
183.90
EPS (Diluted)
0.12
3.30
8.16
5.03
2.41
97.35
Diluted Shares Outstanding
1,125.00
1,602.20
2,719.30
3,382.50
7,292.30
183.90
EBITDA
140.20
1,670.80
13,943.60
20,570.00
20,995.90
14,575.40
Preferred Dividends
-
-
7,844.60
-
-
8,451.90

About ContraVir Pharmaceuticals

View Profile
Address
399 Thornall Street
Edison New Jersey 08837
United States
Employees -
Website http://www.contravir.com
Updated 07/08/2019
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.